In Massachusetts, Hatfield previously also worked at Bristol-Myers Squibb (BMS). He earned an MBA from The Wharton School of the University of Pennsylvania and a Bachelor’s degree in pharmacy from Purdue University. He isn’t new to Board memberships, having served or currently serving on Boards for Ambit Biosciences and Biotechnology Industry Organization (BIO). Invivo focuses on treatment of spinal cord injuries using biomaterials and biotechnology, which is a good fit for Hatfield who told The Atlantic “I’m personally very motivated and excited by the company’s work, as I’ve had direct experience with a family member who suffered a serious spinal cord injury at an early age,” Hatfield said. “I’m hopeful that Mark and the InVivo team can make a meaningful difference to the lives of those suffering these kinds of traumatic injury.”
Latest article
Meatable hosts distinguished guests for EU’s first cultivated meat tasting
In the Netherlands, Meatable has hosted the European Union’s first cultivated meat tasting. Michelin-starred chef Ron Blaauw; Constantijn van Oranje, Prince of the Netherlands...
Cool as a cucumber (coating): Sweden’s Saveggy raises $2.1 million for edible produce preserver
In Sweden, foodtech startup Saveggy has raised €1.76 (US$2.1 million) to scale up an edible cucumber coating made from a proprietary formula of canola...
Designer develops chitin-based seed pods
In New York, designer Mara Zimmerman has developed SEAD, a seed delivery and cultivation material made from discarded seafood cells.
Specifically, Zimmerman uses chitin from...